CN104126125B - 慢性阻塞性肺疾病患者的结果的预测 - Google Patents

慢性阻塞性肺疾病患者的结果的预测 Download PDF

Info

Publication number
CN104126125B
CN104126125B CN201380009139.6A CN201380009139A CN104126125B CN 104126125 B CN104126125 B CN 104126125B CN 201380009139 A CN201380009139 A CN 201380009139A CN 104126125 B CN104126125 B CN 104126125B
Authority
CN
China
Prior art keywords
risk assessment
prognosis
use according
patients
bode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380009139.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104126125A (zh
Inventor
S·吉尔斯多夫
M·塔姆
D·斯托尔兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47780019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104126125(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of CN104126125A publication Critical patent/CN104126125A/zh
Application granted granted Critical
Publication of CN104126125B publication Critical patent/CN104126125B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380009139.6A 2012-03-08 2013-02-26 慢性阻塞性肺疾病患者的结果的预测 Active CN104126125B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12001590.4A EP2637023A1 (en) 2012-03-08 2012-03-08 Prediction of outcome in patients with chronic obstructive pulmonary disease
EP12001590.4 2012-03-08
PCT/EP2013/000558 WO2013131621A1 (en) 2012-03-08 2013-02-26 Prediction of outcome in patients with chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
CN104126125A CN104126125A (zh) 2014-10-29
CN104126125B true CN104126125B (zh) 2017-03-01

Family

ID=47780019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380009139.6A Active CN104126125B (zh) 2012-03-08 2013-02-26 慢性阻塞性肺疾病患者的结果的预测

Country Status (11)

Country Link
US (1) US20150080246A1 (cg-RX-API-DMAC7.html)
EP (3) EP2637023A1 (cg-RX-API-DMAC7.html)
JP (1) JP6117251B2 (cg-RX-API-DMAC7.html)
CN (1) CN104126125B (cg-RX-API-DMAC7.html)
BR (1) BR112014019349A8 (cg-RX-API-DMAC7.html)
DK (1) DK2823314T3 (cg-RX-API-DMAC7.html)
ES (1) ES2631653T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN07813A (cg-RX-API-DMAC7.html)
RU (1) RU2688168C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013131621A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405610B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
EP2637023A1 (en) 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
WO2016075054A1 (en) * 2014-11-12 2016-05-19 Koninklijke Philips N.V. Apparatus and method for assessing the severity of chronic obstructive pulmonary disease, copd, in a subject
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA2986097A1 (en) * 2015-05-18 2016-11-24 The University Of British Columbia Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
CN107229813A (zh) * 2016-03-24 2017-10-03 深圳中迈数字医疗技术有限公司 实施监护的判断方法及系统
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) * 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
CA3052349C (en) * 2017-02-02 2024-06-04 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event
WO2018191560A1 (en) * 2017-04-12 2018-10-18 Proterixbio, Inc. Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms
CN107267658B (zh) * 2017-08-21 2018-11-02 常州市第二人民医院 Copd诊断用分子标志物
JP7291688B2 (ja) * 2017-09-13 2023-06-15 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
EP4027145A1 (en) * 2017-09-13 2022-07-13 B.R.A.H.M.S GmbH Pro-adm for therapy monitoring of intensive care unit patients
JP7366007B2 (ja) * 2017-09-13 2023-10-20 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
CN109218131B (zh) * 2018-09-03 2022-03-29 平安医疗健康管理股份有限公司 网络监控方法、装置、计算机设备和存储介质
US20220196678A1 (en) * 2019-02-21 2022-06-23 B.R.A.H.M.S. Gmbh Method for the diagnosis of macce in patients who underwent gastrointestinal surgery
FR3094491B1 (fr) * 2019-03-28 2024-07-19 Rheonova Méthode in vitro de diagnostic, de stratification, de pronostic et/ou de suivi d'une maladie des poumons et/ou une maladie respiratoire
CN110850006B (zh) * 2019-12-20 2020-11-20 河南中医药大学 一种慢性阻塞性肺病诊断试剂及试剂盒

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1751128A (zh) * 2002-12-24 2006-03-22 博适公司 用于区分性诊断的标志物和其应用方法
WO2007131031A2 (en) * 2006-05-02 2007-11-15 Critical Care Diagnostics, Inc. Diagnosis of pulmonary and/or cardiovascular disease
WO2008077958A2 (en) * 2006-12-22 2008-07-03 Hvidovre Hospital Soluble urokinase plasminogen activator receptor (supar) as marker for diseases
CN101553733A (zh) * 2006-10-01 2009-10-07 布拉姆斯股份公司 与心功能不全相关的呼吸道和肺部感染或炎性疾病的诊断
CN101563613A (zh) * 2006-11-12 2009-10-21 布拉姆斯股份公司 借助抗利尿激素原、特别是和肽素或ⅱ型后叶激素运载蛋白对呼吸道和肺部的感染及慢性病的诊断和风险性分级
WO2009129454A2 (en) * 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
CN101611314A (zh) * 2006-12-20 2009-12-23 布拉姆斯股份公司 利用新颖标志物CT-proADM进行诊断和危险分层
CN101688869A (zh) * 2007-05-08 2010-03-31 布拉姆斯股份公司 利用NT-proET-1的诊断和风险分层
CN102253220A (zh) * 2011-06-07 2011-11-23 复旦大学附属中山医院 用于诊断慢性阻塞性肺病急性加重期的试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100159474A1 (en) * 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
GB0911007D0 (en) * 2009-06-25 2009-08-12 Univ Hospital Of North Staffordshire Analyzer apparatus and methods for lung disease
EP2637023A1 (en) 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1751128A (zh) * 2002-12-24 2006-03-22 博适公司 用于区分性诊断的标志物和其应用方法
WO2007131031A2 (en) * 2006-05-02 2007-11-15 Critical Care Diagnostics, Inc. Diagnosis of pulmonary and/or cardiovascular disease
CN101553733A (zh) * 2006-10-01 2009-10-07 布拉姆斯股份公司 与心功能不全相关的呼吸道和肺部感染或炎性疾病的诊断
CN101563613A (zh) * 2006-11-12 2009-10-21 布拉姆斯股份公司 借助抗利尿激素原、特别是和肽素或ⅱ型后叶激素运载蛋白对呼吸道和肺部的感染及慢性病的诊断和风险性分级
CN101611314A (zh) * 2006-12-20 2009-12-23 布拉姆斯股份公司 利用新颖标志物CT-proADM进行诊断和危险分层
WO2008077958A2 (en) * 2006-12-22 2008-07-03 Hvidovre Hospital Soluble urokinase plasminogen activator receptor (supar) as marker for diseases
CN101688869A (zh) * 2007-05-08 2010-03-31 布拉姆斯股份公司 利用NT-proET-1的诊断和风险分层
WO2009129454A2 (en) * 2008-04-18 2009-10-22 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
CN102253220A (zh) * 2011-06-07 2011-11-23 复旦大学附属中山医院 用于诊断慢性阻塞性肺病急性加重期的试剂盒

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Amino-Ternminal Pro-Brain Natriuretic Peptide for the Diagonosis of Acute Heart Failure in Patients With Previous Obstructive Airway Disease.;Roderick H.Tung, MD, et al.;《ANNALS OF EMERGENCY MEDICINE》;20060731;第48卷(第1期);第66-74页 *
Antibiotic Treatment of Exacerabtions of COPD.;Daiana Stolz, MD, et al.;《CHEST》;20070131;第131卷(第1期);第9-19页 *
Biomarkers in lower respiratory tract infections.;Francesco Blasi, et al.;《Pulmonary Pharmacology&Therapeutics》;20101231;第23卷(第6期);第501-507页 *
Biomarkers in the management of COPD.;A.Lacoma, et al.;《EUROPEAN RESPIRATORY REVIEW》;20090630;第18卷(第112期);第96-104页 *
B-Type Natriuretic Peptide Levels in Patients with COPD and Normal Right Ventricular Function.;Gokmen Gemici, et al.;《ADVENCES IN THERAPY》;20080731;第25卷(第7期);第674-680页 *
Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.;B.MULLER, et al.;《Journal of Internal Medicine》;20061231;第260卷(第6期);第568-576页 *
Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD.;Daiana Stolz, MD, et al.;《CHEST》;20070430;第131卷(第4期);第1058-1067页 *
Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease.;C.D.Vizza, et al.;《Regulatory Peptides》;20050131;第124卷(第1-3期);第187-193页 *
Plasma adrenomedullin and endothelin-1 concentration during low-dose dobutamine infusion: Relationship between pulmonary uptake and pulmonary vascular pressure/flow characteristics.;Carmine Dario Vizza, et al.;《Regulatory Peptides》;20061030;第136卷(第1-3期);第85-91页 *
Plasma N-terminal Pro-brain Natriuretic Peptide: A Prognostic Marker in Patients with Chronic Obstructive Pulmonary Disease.;Su Young Chi, et al.;《Lung》;20120114;第190卷(第3期);第271-276页 *
Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD.;Daiana Stolz, MD; et al.;《CHEST》;20080830;第134卷(第2期);第263-272页 *
Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study.;Cedric Daubin, et al.;《BMC Infections Diseases》;20081023;第8卷(第145期);第1-8页 *
Serum vascular endothelial growth factor and its receptor level in patients with chronic obstructive pulmonary disease.;Dorota Kierszniewska-Stepien, et al.;《European Cytokine Network》;20060331;第17卷(第1期);第75-79页 *
血清合肽素、降钙素原对COPD急性加重患者临床风险预测的价值;吴丽芳,等;《东南大学学报(医学版)》;20120229;第31卷(第1期);第47-50页 *

Also Published As

Publication number Publication date
DK2823314T3 (en) 2017-07-03
ZA201405610B (en) 2015-12-23
ES2631653T3 (es) 2017-09-01
BR112014019349A2 (cg-RX-API-DMAC7.html) 2017-06-20
EP2823314A1 (en) 2015-01-14
WO2013131621A8 (en) 2014-06-12
EP2823314B1 (en) 2017-04-12
EP2637023A1 (en) 2013-09-11
BR112014019349A8 (pt) 2017-07-11
IN2014DN07813A (cg-RX-API-DMAC7.html) 2015-07-10
EP3232201A1 (en) 2017-10-18
HK1198556A1 (en) 2015-05-15
CN104126125A (zh) 2014-10-29
RU2014140608A (ru) 2016-04-27
US20150080246A1 (en) 2015-03-19
RU2688168C2 (ru) 2019-05-20
WO2013131621A1 (en) 2013-09-12
JP2015509596A (ja) 2015-03-30
JP6117251B2 (ja) 2017-04-19

Similar Documents

Publication Publication Date Title
JP6117251B2 (ja) 慢性閉塞性肺疾患の患者の転帰予測
CN102317790B (zh) Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用
JP5890427B2 (ja) 非特異的症状を有する患者の予後及びリスク評価
CN107085114B (zh) 用于预测初次不利事件的生物标志物
CN104303061B (zh) 患有疑似慢性心力衰竭的患者中不良事件的预后
CN102203621A (zh) 用于初次慢性肾脏疾病的发展的预后生物标志物
CN101553733B (zh) 与心功能不全相关的呼吸道和肺部感染或炎性疾病的诊断
Huszar et al. Comparative measurement of thromboxane A2 metabolites in exhaled breath condensate by different immunoassays
JP6250351B2 (ja) 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
US20130344506A1 (en) Seprase as a marker for chronic obstructive pulmonary disease (copd)
HK1198556B (en) Prediction of outcome in patients with chronic obstructive pulmonary disease
HK1163813B (en) Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath
HK1164999A (en) Biomarker for the prediction of first adverse events
HK1187101A (en) Prognosis and risk assessment of patients with non-specific complaints
HK1187101B (en) Prognosis and risk assessment of patients with non-specific complaints
HK1203611B (en) Prognosis of adverse events in patients with suspected chronic heart failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198556

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1198556

Country of ref document: HK